Gilead Sciences, Inc. (GILD) — Business segments and KPIs
Revenue by business segment and geography for Gilead Sciences, Inc., with year-over-year trends.
FY 2025
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| Products, Other HIV | 20.75B | 79.7% |
| Cell Therapy Products, Total Cell Therapy Product Sales | 2.18B | 8.4% |
| Trodelvy | 1.40B | 5.4% |
| Veklury | 911M | 3.5% |
| Other Products, Total Other product sales | 799M | 3.1% |
| Revenue by region | ||
| UNITED STATES | 20.88B | 70.9% |
| Europe | 5.06B | 17.2% |
| Other International | 3.50B | 11.9% |